645 Preclinical development of a novel colon-targeted therapeutic for the treatment of immune checkpoint inhibitor (ICI)-colitis
Main Authors: | Sumanta Pal, Nazli Dizman, JoAnn Hsu, Nicholas Salgia, Milton L Greenberg, Andrew C Newman, Jonathan Skupsky, Zeynep Zengin, Luis Meza, Neal Chawla, Sabrina Salgia, Jasnoor Malhotra |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2020-11-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Similar Items
-
Concomitant Radioembolization and Immune Checkpoint Inhibition in Metastatic Renal Cell Carcinoma
by: Jacob J. Adashek, et al.
Published: (2018-05-01) -
Circulating cytokines associated with clinical response to systemic therapy in metastatic renal cell carcinoma
by: Marcin Kortylewski, et al.
Published: (2021-03-01) -
Characterizing the relationships between tertiary and community cancer providers: Results from a survey of medical oncologists in Southern California
by: Nicholas J. Salgia, et al.
Published: (2021-08-01) -
The gut microbiome and response to immune checkpoint inhibitors: preclinical and clinical strategies
by: Jun Gong, et al.
Published: (2019-03-01) -
Tivozanib in renal cell carcinoma: a new approach to previously treated disease
by: Nicholas J. Salgia, et al.
Published: (2020-05-01)